Johannesburg - Healthcare company Adcock Ingram Holdings [JSE:AIP] said on Tuesday that it had been awarded 4% of the South African government's new antiretroviral (ARV) tender by value, which amounts to R166.5m, and 3.2% by volume for a two-year period.
National Treasury announced the results of the new ARV tender late Monday.
The products awarded to Adcock Ingram include 60% of the total volume for Zidovudine 300mg tablets and 70% of the total volume for Efavirenz 50mg capsules, the group said.
In June 2008, Adcock Ingram was awarded a value of R663m for the supply of Efavirenz 600mg tablets for the period June 2008 to May 2010. The total value of the previous tender was R3.172bn.
The total value of the state's ARV tender is R4.162bn and the volume is 116.9 million units of tablets, capsules and liquid preparations. The term of the contract to provide these products is January 1, 2011 to December 31, 2012, Adcock Ingram said.
National Treasury announced the results of the new ARV tender late Monday.
The products awarded to Adcock Ingram include 60% of the total volume for Zidovudine 300mg tablets and 70% of the total volume for Efavirenz 50mg capsules, the group said.
In June 2008, Adcock Ingram was awarded a value of R663m for the supply of Efavirenz 600mg tablets for the period June 2008 to May 2010. The total value of the previous tender was R3.172bn.
The total value of the state's ARV tender is R4.162bn and the volume is 116.9 million units of tablets, capsules and liquid preparations. The term of the contract to provide these products is January 1, 2011 to December 31, 2012, Adcock Ingram said.